DCTH — Delcath Systems Share Price
0.000.00%
Last trade - 00:00- $228.68m
- $208.91m
- $2.07m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 15.32 | ||
| Price to Tang. Book | 15.32 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 48.61 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -176.36% | ||
| Return on Equity | -6449.35% | ||
| Operating Margin | -871.17% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.58 | 1.65 | 3.56 | 2.72 | 2.06 | 27.95 | 70.92 | -9.53% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO KIT is a drug/device combination product designed to administer high-dose chemotherapy directly into the liver while limiting systemic exposure and associated side effects. In Europe, the hepatic delivery system is a stand-alone medical device having the same device components as HEPZATO KIT, but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
Directors
- Roger Stoll NEC (78)
- Gerard Michel CEO (57)
- John Purpura COO (59)
- David Hoffman CCO
- Anthony Dias VFN (50)
- Gilad Aharon IND (47)
- Elizabeth Czerepak IND (65)
- Steven Salamon IND (55)
- John Sylvester IND (57)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- August 5th, 1988
- Public Since
- October 19th, 2000
- No. of Shareholders
- 57
- No. of Employees
- 76
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 27,785,803
- Address
- 566 Queensbury Avenue, QUEENSBURY, 12804
- Web
- https://delcath.com/
- Phone
- +1 5187438892
- Auditors
- Marcum LLP
Upcoming Events for DCTH
Q3 2024 Delcath Systems Inc Earnings Release
Similar to DCTH
Accelerate Diagnostics
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
Agendia NV
NASDAQ Capital Market
FAQ
What is the Delcath Systems share price?
As of Today at 20:13 UTC, shares in Delcath Systems are trading at $8.06. This share price information is delayed by 15 minutes.
How has the Delcath Systems share price performed this year?
Shares in Delcath Systems last closed at $8.06 and the price had moved by +49.81% over the past 365 days. In terms of relative price strength the Delcath Systems share price has outperformed the S&P500 Index by +19.21% over the past year.
What are the analyst and broker recommendations for Delcath Systems?
The overall consensus recommendation for Delcath Systems is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Delcath Systems dividend yield?
Delcath Systems does not currently pay a dividend.
Does Delcath Systems pay a dividend?
Delcath Systems does not currently pay a dividend.
When does Delcath Systems next pay dividends?
Delcath Systems does not currently pay a dividend.
How do I buy Delcath Systems shares?
To buy shares in Delcath Systems you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Delcath Systems?
As of the previous close price of $8.06, shares in Delcath Systems had a market capitalisation of $223.95m.
Where are Delcath Systems shares listed?
Here are the trading details for Delcath Systems:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: DCTH
What kind of share is Delcath Systems?
Based on an overall assessment of its quality, value and momentum Delcath Systems is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Delcath Systems share price forecast for 2024?
The analyst consensus target price for shares in Delcath Systems is $19.83. That is 146.03% above the last closing price of $8.06.
Analysts covering Delcath Systems currently have a consensus Earnings Per Share (EPS) forecast of -$1.28 for the next financial year.
What is the trend in the Delcath Systems share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Delcath Systems. Over the past six months, its share price has outperformed the S&P500 Index by +75.62%.
As of the last closing price of $8.06, shares in Delcath Systems were trading +77.75% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Delcath Systems PE Ratio?
The Delcath Systems PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $8.06.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Delcath Systems?
Delcath Systems' management team is headed by:
- Roger Stoll - NEC
- Gerard Michel - CEO
- John Purpura - COO
- David Hoffman - CCO
- Anthony Dias - VFN
- Gilad Aharon - IND
- Elizabeth Czerepak - IND
- Steven Salamon - IND
- John Sylvester - IND